Early Hormone Replacement Therapy Linked to Lower Heart Disease Risk in Women
A new study published in JAMA Internal Medicine has found that women who begin hormone replacement therapy (HRT) during perimenopause or early postmenopause may experience a 22% reduction in cardiovascular disease risk compared to those who do not use hormone therapy. This research builds on previous findings that have established a higher risk of cardiovascular disease in women post-menopause, attributed to factors such as decreased estrogen levels, stiffening of blood vessels, and changes in cholesterol and metabolism. The study analyzed data from over 2,700 women participating in the Study of Women’s Health Across the Nation (SWAN) project, focusing on those who reported menopause-related symptoms like hot flashes and night sweats, and had no prior heart disease diagnosis. Dr. Samar R. El Khoudary, a key researcher in the study, emphasized that much of the existing research has primarily focused on women who are already postmenopausal, leaving a gap in understanding the effects of hormone therapy during the earlier stages of menopause. The findings suggest that initiating hormone therapy within 10 years of menopause onset could lead to an even greater reduction in heart disease risk, particularly among Black women, who showed a 49% lower risk. However, El Khoudary cautioned that as this was an observational study, the results should be interpreted with caution due to potential confounding factors. Experts like Dr. Jennifer Wong and Dr. Prudence Hall, who were not involved in the study, noted the significance of these findings and the need for further research to identify which women might benefit most from early hormone therapy. They highlighted the importance of addressing vasomotor symptoms that can accompany menopause, as these may indicate a higher cardiovascular risk. Overall, the study underscores the need for personalized approaches to hormone therapy, considering both timing and individual health profiles.




